

## ASCVD Risk Reduction Primary and Secondary Prevention

Always counsel patient on **lifestyle interventions:** emphasizing exercise, weight loss, heart healthy diet.

### Secondary Prevention:

History of Symptomatic CAD (MI, Revascularization, Angina), Ischemic Stroke, Symptomatic PAD or History of Revascularization/Amputation, Familial Hypercholesterolemia, CKD 3/4 (**NOT Hemodialysis**)

#### 1. Lifelong **HIGH** Intensity Statin

- If not tolerated then **Medium** Intensity Statin + Ezetimibe

If LDL > 70 despite **adherence** on **HIGH** intensity statin, then add Ezetimibe

If LDL > 70 despite **adherence** on **HIGH** intensity statin and Ezetimibe, add PCSK9-1

1. Statin -> 2. Ezetimibe -> 3. PCSK9-1

### Primary Prevention Treatment Indications

See detailed flowsheets that follow for additional information.

LDL > 190

- HIGH intensity statin and work-up for familial disorder consider Ezetimibe and PCSK9-1

DM2 and Age 40 to 75

- MODERATE intensity statin  
- based on other risk factors consider HIGH intensity statin (see chart on following pages)

ASCVD 10 Year Risk > 20%

ASCVD 10 Year Risk > 7.5% and < 20%

- If significant other RFs or lifetime risk > 39%  
- Favor to start MODERATE Intensity Statin

### Shared Decision Making Required

Especially for those with **NO CVD risk equivalent** such as:

- DM2, LDL > 190, 10 year ASCVD risk > 20%, CKD 3/4

Use Mayo Clinic Statin Choice Decision Aid: <https://statindecisionaid.mayoclinic.org/>

## Medication and Lab Tips

Preferred Statins at St. Vincent's

1. Rosuvastatin, 2. Atorvastatin, 3. Pravastatin

1st Line, no comorbidities:

**Rosuvastatin**

- most potent
- less drug interactions
- hydrophilic (lower risk for cognitive SEs)
- long half life (dose at anytime)

1st Line, CKD 3 / 4:

**Atorvastatin**

- high intensity
- not renally cleared
- long half life (dose at anytime)

1st Line, Liver Disease (LFTs > 3Xs ULN, stable chronic liver disease) or Statin Intolerance due to SEs including myalgias:

**Pravastatin**

- clinical trial shows safety in liver disease
- medium intensity
- less drug interactions
- hydrophilic (lower risk for cognitive)

### Hemodialysis:

- Multiple clinical trials has shown no definitive benefit
- Only consider in patients with high LDL levels > 150

Order a **NON-fasting** Lipid panel for screening, inconvenient and not necessary to order fasting; if TG extremely high can do fasting

### Statin Intensity Dosing Chart

Drug	<u>Low</u>	<u>Moderate</u>	<u>High</u>
Rosuvastatin	NA	5 to 10	20 to 40
Atorvastatin	NA	10 to 20	40 to 80
Pravastatin	10 to 20	40 to 80	NA

\***Low: LDL Dec < 30%; Moderate: LDL Dec 30 to 50%, High: LDL Dec > 50%**

### Notes of commonly prescribed statins

**Simvastatin:** **NOT HIGH intensity, multiple drug interactions including with amlodipine,** take at night versus other statins recommended can take at most convenient time, lipophilic, short half-life

**Lovastatin:** not a potent statin, can use if only need small reductions in LDL, lipophilic, short half-life

### Risk Calculators to Use:

<https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/>

- LDL optional, only need total and HDL cholesterol

### Lab Tips When Prescribing Statins

- **Baseline Labs:** CMP (BMP + LFTs), CK, TSH, Pregnancy Test

- **CK:** only at initiation unless concern for muscle injury

- **Liver:** if LFTs > than 3 times ULN, consider pravastatin or lower dose of rosuvastatin; no routine monitoring required during statin therapy; hepatic failure due to statins is EXTREMELY RARE and liver dysfunction due to statins is not a significant concern

- **Thyroid:** hypothyroidism is a cause of hyperlipidemia and predisposes to muscle injury, only at initiation